Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Girona – page 19

302 clinical trials in Girona, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Girona at a glance
302
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

302 trials in Girona

Open in trial search

Plasma cell myeloma

Not recruiting

Study of Daratumumab with Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Cervix carcinoma

Not recruiting

Study of Dostarlimab for Patients with High-Risk Locally Advanced Cervical Cancer After Chemo-Radiation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Non-small cell lung cancer stage III+5

Not recruiting

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ociperlimab
  • Sponsor:Beigene Ltd.

Plasma cell myeloma

Not recruiting

Study on Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Small cell lung cancer extensive stage

Not recruiting

Study of Pembrolizumab, Lenvatinib, and Chemotherapy for First-Line Treatment in Extensive-Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Fundacion GECP

Non-small cell lung cancer+1

Not recruiting

Study of Chemotherapy and Nivolumab Before and After Surgery for Patients with Non-Small Cell Lung Cancer in the Upper Lung Area

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Girona

What the registry says about research in the country

01 Neurology & Stroke Treatment

Innovative research focusing on acute ischemic stroke treatments, including studies evaluating new therapies to improve functional outcomes and neurological recovery.

  • Stroke recovery assessment
  • Neurological function improvement
  • Reperfusion optimization

Multiple trials exploring breakthrough treatments for patients with cerebral ischemic conditions.

02 Respiratory & Viral Diseases

Comprehensive studies on respiratory infections, including trials for RSV, hMPV, and COVID-19 vaccines, particularly focusing on vulnerable populations.

  • Vaccine efficacy studies
  • Immunogenicity assessment
  • Combined vaccine research

Special attention to developing protective measures for adults over 60 years of age.

03 Oncology Research

Groundbreaking studies in cancer treatment, including trials for breast cancer, prostate cancer, and leukemia using innovative therapeutic approaches.

  • Triple-negative breast cancer therapy
  • Chronic myeloid leukemia treatment
  • Metastatic cancer management

Focus on developing targeted therapies and improving treatment outcomes across various cancer types.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.